Cumulative risk of HL in first-degree relatives of HL patients by histology of HL patient in the family compared with the population risk
| Histology of HL patient in family . | Cumulative risk % in a relative by age (y) . | Lifetime risk . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0-9 . | 0-19 . | 0-29 . | 0-39 . | 0-49 . | 0-59 . | 0-69 . | 0-79 . | 95% CI . | No. . | |
| Any HL | 0.0 | 0.1 | 0.3 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.4-0.6 | 147 |
| Classical | 0.0 | 0.1 | 0.3 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.4-0.6 | 63 |
| Nodular sclerosis | 0.0 | 0.2 | 0.3 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.3-0.6 | 42 |
| Lymphocyte-rich | 0.0 | 0.1 | 0.5 | 0.7 | 0.8 | 0.9 | 0.9 | 0.9* | 0.4-1.4 | 12 |
| Mixed cellularity | 0.0 | 0.1 | 0.2 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.2-0.6 | 12 |
| Population risk | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.3-0.3 | 28 732 |
| Histology of HL patient in family . | Cumulative risk % in a relative by age (y) . | Lifetime risk . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0-9 . | 0-19 . | 0-29 . | 0-39 . | 0-49 . | 0-59 . | 0-69 . | 0-79 . | 95% CI . | No. . | |
| Any HL | 0.0 | 0.1 | 0.3 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.4-0.6 | 147 |
| Classical | 0.0 | 0.1 | 0.3 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.4-0.6 | 63 |
| Nodular sclerosis | 0.0 | 0.2 | 0.3 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.3-0.6 | 42 |
| Lymphocyte-rich | 0.0 | 0.1 | 0.5 | 0.7 | 0.8 | 0.9 | 0.9 | 0.9* | 0.4-1.4 | 12 |
| Mixed cellularity | 0.0 | 0.1 | 0.2 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.2-0.6 | 12 |
| Population risk | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.3-0.3 | 28 732 |
Example: The lifetime 0-79 y cumulative risk of HL in a person with a first-degree relative diagnosed with lymphocyte-rich HL was 0.9%, whereas the risk in the general population was 0.3%.